Oct 13,2022

Evaluating the Feasibility of a Digital Therapeutic Program for Patients With Cancer During Active Treatment: Pre-Post Interventional Study

Increasing evidence shows that lifestyle interventions can improve the symptoms, quality of life (QoL), and even overall survival of patients with cancer. Digital therapeutics (DTx) can help implement behavioral modifications and empower patients through education, lifestyle support, and remote symptom monitoring. The study aimed to test the feasibility of a DTx program from Sidekick Health for patients with cancer, as measured by engagement, retention, and acceptability, in a 4-week single-arm trial in Iceland, where DTx was delivered through a smartphone app. The high retention, engagement, and acceptability found in this study demonstrate that multidisciplinary DTx is feasible for patients with cancer. A longer, full-scale randomized controlled trial is currently being planned to evaluate the efficacy of the intervention.

CLINICAL STUDY

#dtx

#mobile app

#coaching

View Analyst & Ambassador Comments
Go to original news
Jun 08,2023

COTA-Powered Research will be Presented at the Annual Congress of the European Hematology Association

The fruits of COTA’s expanded research and consulting services — Real-World Insights and Real-World Support — will be on display at the annual Congress of the European Hematology Association (EHA) being held in Frankfurt and online June 8-11. DLBCL is the most common subtype of non-Hodgkin lymphoma. Standard of care for frontline therapy remains chemoimmunotherapy; however, nearly half of the patients will experience relapse or refractory (R/R) disease. A research team from COTA and Merck Sharp & Dohme, a subsidiary of Merck & Co., analyzed RWD from 1347 eligible patients, the majority of whom (81.3%) received treatment in the community practice setting. The study concludes that there is a significant need for improved therapy options for patients who do not respond to the current initial standard of care.

CLINICAL STUDY

#rwd

#rwe

View Analyst & Ambassador Comments
Go to original news
Jun 07,2023 TOP STORY

ASCO: AI-powered MOSAIC will build 3D atlas for cancer

The project – dubbed MOSAIC (Multi Omic Spatial Atlas in Cancer) – brings together a string of academic cancer research organisations, as well as artificial intelligence company Owkin, which specialises in machine learning models used to find new biomarkers and therapeutic targets from patient samples and spatial biology company NanoString. MOSAIC is starting life with $50 million in funding from Owkin, and will use a technique known as ‘spatial omics’, which combines gene sequencing with imaging technologies to analyse RNA and proteins not just for their presence or quantity, but also where they are physically located in cells and the microenvironment they inhabit. MOSAIC will focus initially on cancers with unmet medical needs, including non-small cell lung cancer, triple-negative breast cancer, diffuse large B cell lymphoma, ovarian cancer, glioblastoma, mesothelioma, and bladder cancer, said the partners.

CLINICAL STUDY

#ai/software

View Analyst & Ambassador Comments
Go to original news
Jun 02,2023 TOP STORY

ASCO: Grail’s cancer blood test ‘promising’ in UK trial

Researchers in the UK say Grail’s blood test for more than 50 different types of cancer has shown promise in a trial involving thousands of people with suspected cancer symptoms. The team at Oxford University found that the Galleri multi-cancer early detection (MCED) test detected a cancer signal in 323 people presenting at a GP with suspected symptoms, 244 of whom subsequently had cancer diagnosed, giving a positive predictive accuracy of 75% in the 6,238-patient SYMPLIFY trial. The test was able to rule out cancer with around 98% predictive efficacy – meaning around 2% of patients with a negative result actually had cancer, and overall the test correctly revealed cancer 66% of the time. The SYMPLIFY trial is one of two large-scale community trials of the Galleri test being carried out in the UK, along with the NHS-Galleri study, which is evaluating it in up to 140,000 subjects and due to generate results sometime later this year.

CLINICAL STUDY
View Analyst & Ambassador Comments
Go to original news
Jun 02,2023

New Data from Immunotherapy Quality of Life Study Accepted for Two Abstracts at 2023 ASCO

The Wave Health digital health platform, used to collect patient symptom and quality of life information in an innovative research study, comprises two abstracts accepted to the 2023 ASCO Annual Meeting. The study used TTI’s electronic patient reported outcomes (ePRO) platform to measure a variety of symptoms and aspects of health-related quality of life (HRQoL) in the “ImmunoWave” study, conducted at Fred Hutchinson Cancer Center. The study assessed for the presence of eleven symptoms and overall quality of life in a group of participants with prior exposure to ICI therapy or ongoing long-term ICI treatment. Participants in the study completed weekly symptom and HRQoL assessments using Wave Health. Participants reported frequent, persistent, and often severe symptoms, most notably fatigue, mental health symptoms and musculoskeletal symptoms. The study also identified which symptoms appeared to correlate most with diminished quality of life.

CLINICAL STUDY

#rwd

#mobile app

View Analyst & Ambassador Comments
Go to original news
May 31,2023

Predicting benefit from immune checkpoint inhibitors in patients with non-small-cell lung cancer by CT-based ensemble deep learning: a retrospective study

Only around 20–30% of patients with non-small-cell lung cancer (NCSLC) have durable benefit from immune-checkpoint inhibitors. Although tissue-based biomarkers (eg, PD-L1) are limited by suboptimal performance, tissue availability, and tumour heterogeneity, radiographic images might holistically capture the underlying cancer biology. In this study the researchers aimed to investigate the application of deep learning on chest CT scans to derive an imaging signature of response to immune checkpoint inhibitors and evaluate its added value in the clinical context. At the end, this proof-of-concept study shows that automated profiling of radiographic scans through deep learning can provide orthogonal information independent of existing clinicopathological biomarkers, bringing the goal of precision immunotherapy for patients with NSCLC closer.

CLINICAL STUDY

#ml

View Analyst & Ambassador Comments
Go to original news
May 25,2023

Lunit Demonstrates Predictive Value of AI-Biomarker Platform at the 2023 ASCO Annual Meeting

Lunit, a global leader of AI-powered cancer diagnostics and therapeutics solutions, is set to make a significant impact at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois. This year, Lunit will present 16 abstracts at the conference, showcasing the groundbreaking capabilities of its AI-biomarker platform, Lunit SCOPE. A study using Lunit SCOPE IO in head and neck squamous cell carcinoma (HNSCC) patients undergoing immunotherapy demonstrated a shift towards an inflamed immune phenotype, leading to improved outcomes in patients treated with neoadjuvant durvalumab, with or without tremelimumab. Another clinical trial, evaluating the efficacy of neoadjuvant therapy in HPV-positive HNSCC patients, revealed treatment-induced immune changes are strongly associated with treatment outcomes.

CLINICAL STUDY

#ai/software

View Analyst & Ambassador Comments
Go to original news
May 24,2023

New Data Presented at ATS 2023 Reinforce Clinical Utility of Veracyte’s Genomic Tests in Interstitial Lung Disease and Lung Cancer

Veracyte, Inc. (Nasdaq: VCYT) today announced new data suggesting its novel genomic tests may positively impact diagnosis and care for patients being evaluated for interstitial lung disease (ILD) or lung cancer. The findings were presented at ATS 2023, the annual meeting of the American Thoracic Society, which is being held May 21-24 in Washington, D.C.

CLINICAL STUDY
View Analyst & Ambassador Comments
Go to original news
May 12,2023

Veracyte Announces that New Data Show Use of the Prosigna Test Significantly Changed Treatment Decisions for Patients with Early-Stage Breast Cancer

Veracyte announced that new data show the use of the Prosigna Breast Cancer Assay altered treatment decisions for patients with early-stage breast cancer, including significantly reducing the use of chemotherapy among those with clinically high-risk disease. The findings are from EMIT, a prospective, multi-year, population-based study in Norway that is investigating the impact of molecular testing – specifically, the Prosigna test – on breast cancer care and outcomes. For the study, researchers evaluated data for 2,164 women in Norway with early-stage (node-negative) breast cancer, recording physicians’ treatment decisions for these patients before and after a Prosigna test result. Prior to Prosigna results, physicians directed 27% to no systemic treatment (low-risk patients), 38% to endocrine therapy only (intermediate-risk patients) and 35% to chemotherapy followed by endocrine therapy (high-risk patients). After Prosigna test results, these treatment decisions changed to 25%, 51% and 24%, respectively. Notably, for patients assigned to chemotherapy prior to Prosigna results, 45% were de-escalated to endocrine therapy following Prosigna results.

CLINICAL STUDY
View Analyst & Ambassador Comments
Go to original news
May 08,2023

AI Predicts Future Pancreatic Cancer

The findings, published May 8 in Nature Medicine, suggest that AI-based population screening could be valuable in finding those at elevated risk for the disease and could expedite the diagnosis of a condition found all too often at advanced stages when treatment is less effective and outcomes are dismal, the researchers said. Currently, there are no population-based tools to screen broadly for pancreatic cancer. Those with a family history and certain genetic mutations that predispose them to pancreatic cancer are screened in a targeted fashion. But such targeted screenings can miss other cases that fall outside of those categories, the researchers said. In the new study, the AI algorithm was trained on two separate data sets totaling 9 million patient records from Denmark and the United States. The researchers "asked" the AI model to look for telltale signs based on the data contained in the records. Based on combinations of disease codes and the timing of their occurrence, the model was able to predict which patients are likely to develop pancreatic cancer in the future.

CLINICAL STUDY

#ai/software

View Analyst & Ambassador Comments
Go to original news
Subscribe to CLINICAL STUDY